Like their counterparts in France, researchers in the United Kingdom have been monitoring the health of children born to HIV positive women. In particular, they have focused their analysis on birth defects. Their results suggest that birth defects are not increased because of exposure to HAART.
The study team reviewed data on 8, 242 infants, 232 of whom had at least one birth defect.
In the first three months after conception, moving from fertilized egg to fetus, development and growth is extremely rapid. During this time, because of such rapid growth the fetus is exquisitely sensitive to the effects of drugs. So British researchers focused on whether initiating HAART during the first trimester was associated with an increased risk of birth defects compared to other trimesters.
When they took into account maternal factors such as substance use, ethnicity, age and health, there was no significant difference in the risk of birth defects among women initiating HAART in different trimesters.
No particular family or class of anti-HIV drugs was associated with an increased risk of birth defects.
Based on studies in monkeys, efavirenz (Sustiva, and in Atripla) can cause severe birth defects. In the UK study, a total of 220 infants were exposed to efavirenz in the womb. Slightly more than 2% (five infants) developed birth defects, including the following:
But the rate of these birth defects was similar to that seen in children born to HIV negative women who did not take efavirenz.
A similar trend was seen with ddI in that whatever defects occurred were seen at the same rate in children born to HIV negative women.
The most commonly reported birth defects affected the following body parts:
In boys born to HIV negative mothers, a relatively common birth defect, occurring in 1 in 150 or 1 in 300 boys depending on where the study was done, is hypospadias. In this condition, the penis looks abnormal and the opening that is normally at the tip is located somewhere else, usually near the head of the penis. But in a small proportion of cases, this opening can occur on the underside of the penile shaft or even near the scrotum. Hypospadias can be corrected with surgery. There were 12 cases of hypospadias in the British study, all occurring in children exposed to AZT in the womb. However, this finding does not prove that AZT causes hypospadias. A formal clinical trial would be needed to resolve that issue.
The rate of birth defects was nearly 3% in the UK study. In children born to HIV negative women in the UK, the rate is between 2% and 3%. On the European continent, the rate is 2.2%. The results of the British study should reassure HIV positive women who are thinking of having a baby that the use of HAART does not pose a major risk for birth defects.
Want to read more articles in the February 2009 issue of Treatment Update? Click here.